Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-30

Clinical Trial Update: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of daclatasvir and simeprevir in genotype 1 chronic hepatitis C infection; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daklinza (Daclatasvir)
  • Olysio (Simeprevir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2015-11-30